Nandanan Erathodiyil

Dr. Nandanan Erathodiyil is a leading scientist in translational nanomedicine, advancing innovations at the intersection of organic chemistry, biomedical science, and advanced materials. His research focuses on designing next-generation nano-structured biomaterials for precision therapeutics and transformative healthcare solutions.

With a strong commitment to bridging fundamental science and clinical application, he develops cutting-edge nanomedicine platforms, targeted drug delivery systems, and biomaterials for tissue engineering. His multidisciplinary approach enables the creation of intelligent, high-performance nanoplatforms that enhance therapeutic efficacy and address complex biomedical challenges.

Driven by a vision to translate discovery into real-world impact, Dr. Erathodiyil’s work accelerates the journey from laboratory innovation to clinical implementation, contributing to improved patient outcomes and shaping the future of advanced, personalized medicine.

Medicinal and Synthetic Chemistry for Therapeutic Innovation

Design and Synthesis of Medically Relevant Functional Materials

Molecular Engineering of Nano Structured Biomaterials for Tissue Engineering and Regenerative Medicine

Structure-Property Relationships in Therapeutic Nanomaterials

Chemical Design of Targeted and Precision Drug Delivery Systems

Multidisciplinary Integration of Chemistry, Materials Science, and Biomedicine

Advancing Healthcare Through Chemically Enabled Technologies

Dr. Nandanan Erathodiyil is a Senior Scientist in the Department of Bioengineering and Nanomedicine at King Faisal Specialist Hospital and Research Centre (KFSHRC), with extensive experience translating chemical and nanotechnology innovations into clinically relevant solutions. Trained in synthetic organic chemistry, he holds a Ph.D. from CSIR-National Chemical Laboratory, India, and has over two decades of research experience across academia, government research institutes, and biotechnology.

Prior to joining KFSHRC, he held senior and principal research scientist positions at A*STAR institutes in Singapore, including the Institute of Bioengineering and Nanotechnology (IBN) and the Institute of Materials Research and Engineering (IMRE). His experience also includes roles in the U.S. biotechnology sector and prestigious postdoctoral fellowships at NIH, Lawrence Berkeley National Laboratory, and as an Alexander von Humboldt Fellow at the Free University of Berlin. His work focuses on chemistry driven nanomedicine platforms designed to advance precision therapeutics and improve patient outcomes.